Investment Size
First Period 1984-1998
Rougier Biotech:10 million USD invested in:
• Montreal Monoclonal Antibodies production facility
• R&D resulting in 67 mBa and CardioVision™
Rougier Biotech:10 million USD invested in:
• Montreal Monoclonal Antibodies production facility
• R&D resulting in 67 mBa and CardioVision™
• Phase I and II Clinical Trials
for CardioVision™
• Phase III Clinical Trials started - 80 Patients enrolled
• Phase III Clinical Trials started - 80 Patients enrolled
Second Period 1999-2006
Aquisition by Erfa Biotech: 1 million USD invested in:
• Concept Validation
• Product Validation (9000 vials for clinical research)
• IND’s approved by FDA, TPP and EME
• Patent protection extended to 2010
Third Period 2006- to market entry in
2012
Extended Partnership to Market Entry 6 million USD
• Completion of Phase III
• Regulatory Approvals
 |
|
|
|
|
|
|
|
|
|
 |
 |
 |
 |
 |
|
||||
 |
 |
 |
 |
 |
|
||||
 |
|
||||||||